Forte Biosciences, Inc. — Director's Dealing 2017

Apr 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-19

Reporting Person: SCHIMMEL PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-19	Common Stock	C	23464	—	Acquired	23464	Direct
2017-04-19	Common Stock	C	4117	—	Acquired	4117	Indirect
2017-04-19	Common Stock	C	3623	—	Acquired	3623	Indirect
2017-04-19	Common Stock	C	3623	—	Acquired	3623	Indirect
2017-04-19	Common Stock	P	10000	$10.00	Acquired	13623	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-04-19	Series H Preferred Stock	$	C	161906	Disposed		Common Stock (23464)	Direct
2017-04-19	Series F Preferred Stock	$	C	28410	Disposed		Common Stock (4117)	Indirect
2017-04-19	Series G Preferred Stock	$	C	25000	Disposed		Common Stock (3623)	Indirect
2017-04-19	Series G Preferred Stock	$	C	25000	Disposed		Common Stock (3623)	Indirect

Footnotes

F1: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date.

F2: The shares were purchased at the Issuer's initial public offering.